Test Code LAB6209 FSH AND LH
Additional Codes
Labcorp 028480
Specimen Type
Preferred Sample: Serum (SST, Gold, Tiger, Red Top-no gel)
Alternative Sample: Potassium EDTA
Specimen Volume
1 mL
Minimum Volume
0.5 mL
Turnaround Time
STAT: 1 hour
Routine: 4 hours
Test Schedule
Daily
Sample Stability
Refrigerated: 7 days
Frozen: 12 months
Method
Chemiluminescent Microparticle Immunoassay (CMIA)
Reference Ranges
| Test | Male | Female |
|
FSH (mIU/mL) |
0.95-11.95 | Follicular phase: 3.03-8.08 Mid-Cycle phase: 2.55-16.69 Luteal phase: 1.38-5.47 Postmenopause: 26.72-133.41 |
|
LH (mIU/mL) |
0.57-12.07 | Follicular phase: 1.80-11.78 Mid-Cycle phase: 7.59-89.08 Luteal phase: 0.56-14.00 Postmenopause: 5.16-61.99 |
Reporting Limit
Reporting Range FSH: 0.11-750.00 mlU/mL
Reporting Range LH: 0.12-1000.00 mlU/mL
Synonyms
FSH, LH, LAB6209, FOLLICLE STIMULATING HORMONE, LUTEINIZING HORMONE
CPT Codes
83001
83002
Interference
Hemolysis: 500mg/dL
Icterus: 20 mg/dL
Lipemia: 3000mg/dL
Clinical Information
Luteinizing Hormone (LH), together with Follicle Stimulating Hormone (FSH), is secreted by the gonadotroph cells in the pituitary in response to the secretion of the gonadotropin releasing hormone (LHRH, GnRH) from the hypothalamus. Ovarian steroids, principally estrogens, modulate the secretion of LH and FSH which in turn regulate the menstrual cycle in females. When the follicle and the ovum contained within it reach maturity, a surge of LH causes the follicle to rupture releasing the ovum. The follicular remnant is transformed into a corpus luteum, which secretes progesterone and estradiol. During the follicular and luteal phases, LH concentrations are much lower than the levels observed at the time of the LH surge due to estrogens exerting a negative feedback on the release of LH. Shortly before the mid-cycle surge in LH, ovarian steroids, specifically estradiol, exert a positive feedback on the release of LH.
Determination of the concentration of LH is essential for the prediction of ovulation, in the evaluation of infertility, and the diagnosis of pituitary and gonadal disorders. Increasing concentrations of LH precede ovulation and in cases in which the period of optimal fertility needs to be defined for the timing of intercourse or artificial insemination, daily concentrations of LH are important for the prediction of ovulation. At menopause, or following ovariectomy in women, concentrations of estrogens decline. The lowered concentrations of estrogens result in a loss of the negative feedback on gonadotropin release, resulting in an increase of LH and FSH.
The primary role of LH in males is to stimulate the production of testosterone by the Leydig cells. LH, through the production of testosterone together with FSH, regulates spermatogenesis in the Sertoli cells of the seminiferous tubules of the testes. Testosterone exerts a negative feedback on the release of LH. In sexually mature adults, gonadotropin deficiency is usually an early indication of the development of panhypopituitarism. Low concentrations of LH, FSH, and steroids are observed with this disorder. In contrast, gonadotropin secreting tumors of the hypothalamus and pituitary result in elevated concentrations of LH and FSH.
Gonadal failure, a cause of infertility, is indicated by elevated concentrations of LH and FSH accompanied by low concentrations of gonadal steroids. In the female, elevated concentrations of LH can indicate primary amenorrhea, menopause, premature ovarian failure, polycystic ovarian syndrome, hypergonadotropic hypogonadism, or ovulation. In the male, elevated concentrations of LH can result from primary testicular failure, seminiferous tubule dysgenesis (Klinefelter’s syndrome), Sertoli cell failure, anorchia, or hypergonadotropic hypogonadism.
Abnormal FSH concentrations may indicate dysfunction of the hypothalamic-pituitary axis. FSH deficiency along with low concentrations of LH and sex steroids may be due to panhypopituitarism, either from a decrease in the release of GnRH, or from a lack of response of the pituitary to GnRH. Determination of serum FSH, following administration of GnRH, may allow differentiation of these two conditions. Oral contraceptives reduce gonadotropin levels due to negative feedback from these steroids.